newsfilter
← Latest News
Business Wire·

Fibrocell Science Extends Patent Protection for LAVIV® (azficel-T) Through 2031

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), creator of the first FDA-approved autologous cellular product, LAVIV® (azficel-T) for aesthetics, announced today that the United States Patent and Trademark Office (USPTO) has awarded a patent to the Company which covers azficel-T fibroblast suspension, extending the patent exclusivity in the United States until 2031.